BCL2 and acute lymphoblastic leukemia: The choice of AZA+VEN was informed by emerging evidence supporting the efficacy of venetoclax in ETP-ALL, which is highly dependent on the anti-apoptotic protein BCL-2 for survival, unlike more mature T-ALL subtypes that rely on BCL-XL.